Compare KNDI & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KNDI | RFL |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Real Estate |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.8M | 61.1M |
| IPO Year | 2021 | 2017 |
| Metric | KNDI | RFL |
|---|---|---|
| Price | $0.87 | $1.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 166.7K | 102.0K |
| Earning Date | 04-27-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $0.78 | $1.12 |
| 52 Week High | $1.77 | $3.19 |
| Indicator | KNDI | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 37.99 | 46.94 |
| Support Level | $0.81 | $1.15 |
| Resistance Level | $1.12 | $1.32 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 8.05 | 19.94 |
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.